Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)

CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (NCT01243424) is an ongoing, randomized trial in subjects with early type 2 diabetes and increased cardiovascular risk or established complications that will determine the long-term cardiovascular impact of linagliptin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes & vascular disease research 2015-05, Vol.12 (3), p.164-174
Hauptverfasser:	Marx, Nikolaus, Rosenstock, Julio, Kahn, Steven E, Zinman, Bernard, Kastelein, John J, Lachin, John M, Espeland, Mark A, Bluhmki, Erich, Mattheus, Michaela, Ryckaert, Bart, Patel, Sanjay, Johansen, Odd Erik, Woerle, Hans-Juergen
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Biomarkers - blood Blood Glucose - drug effects Blood Glucose - metabolism Cardiovascular Diseases - diagnosis Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Clinical Protocols Clinical Trial Design Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - mortality Dipeptidyl Peptidase 4 - metabolism Dipeptidyl-Peptidase IV Inhibitors - adverse effects Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Double-Blind Method Female Glycated Hemoglobin A - metabolism Humans Incretins - adverse effects Incretins - therapeutic use Linagliptin - adverse effects Linagliptin - therapeutic use Male Middle Aged Patient Selection Research Design Risk Factors Sample Size Sulfonylurea Compounds - adverse effects Sulfonylurea Compounds - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (NCT01243424) is an ongoing, randomized trial in subjects with early type 2 diabetes and increased cardiovascular risk or established complications that will determine the long-term cardiovascular impact of linagliptin versus the sulphonylurea glimepiride. Eligible patients were sulphonylurea-naïve with HbA1c 6.5%–8.5% or previously exposed to sulphonylurea (in monotherapy or in a combination regimen
ISSN:	1479-1641 1752-8984
DOI:	10.1177/1479164115570301